Table 3. Correlation of EGFR expression and FISHa and the clinical features.
| Characteristics | Patients (n=62) | EGFR overexpression (n=51) | EGFR FISH (n=22) | ||
|---|---|---|---|---|---|
| No. (%) | No./Subgroup (%) | P value | No./Subgroup (%) | P value | |
| Age (year) | |||||
| <=65 | 47 (75.8) | 36/47 (76.6) | 0.052b | 17/47 (36.2) | 0.842 |
| >65 | 15 (24.2) | 15/15 (100.0) | 5/15 (33.3) | ||
| Gender | |||||
| Male | 50 (80.6) | 39/50 (78.0) | 0.102b | 18/50 (36.0) | 1.000b |
| Female | 12 (19.4) | 12/12 (100.0) | 4/12 (33.3) | ||
| Performance status | |||||
| 0-1 | 59 (95.2) | 48/59 (81.4) | 1.000b | 22/59 (37.3) | 0.546b |
| 2 | 3 (4.8) | 3/3 (100.0) | 0/3 (0.0) | ||
| Smoking | |||||
| Never | 23 (37.1) | 22/23 (95.7) | 0.042b | 8/23 (34.8) | 0.929 |
| Ever | 39 (62.9) | 29/39 (74.4) | 14/39 (35.9) | ||
| Histologic grade | |||||
| G1 | 6 (9.7) | 5/6 (83.3) | 0.305b | 3/6 (50.0) | 0.004b |
| G2 | 17 (27.4) | 12/17 (70.6) | 11/17 (64.7) | ||
| G3 | 39 (62.9) | 34/39 (87.2) | 8/39 (20.5) | ||
| No. of previous chemotherapy | |||||
| None or 1 | 43 (69.4) | 41/43 (95.3) | <0.001b | 15/43 (34.9) | 0.882 |
| 2 or more | 19 (30.6) | 10/19 (52.6) | 7/19 (36.8) | ||
| Disease extent | |||||
| Locally advanced | 6 (9.7) | 3/6 (50.0) | 0.063b | 2/6 (33.3) | 1.000b |
| Metastatic | 56 (90.3) | 48/56(85.7) | 20/56 (35.7) | ||
a
Fluorescence In Situ Hybridization
b
Tested byFisher's exact test